Kun elektronisk udgave - Sundhedsstyrelsen

More documents

Recommendations

Info

Mitchell P, Smith W, Wang JJ. Iris color, skin sun sensitivity and agerelatedmaculopathy. The Blue Mountains Eye Study. Ophthalmology1998;105:1359-1363. (54)Moisseiev J et al. The impact of macular photocoagulation study on thetreatment of exudative age-related macular degeneration. Arch Ophthalmol1995;113:185-189. (55)MPSG. Persistent and recurrent neovascularization after laser photocoagulationfor subfoveal choroidal neovascularization of age-related maculardegeneration. Arch Ophthalmol 1994;112:489-499. (56)MPSG. Five-year follow-up of fellow eyes of patients with age-relatedmacular degeneration and unilateral extrafoveal choroidal neovascularization.Arch Ophthalmol 1993;111:1189-1199. (57)MPSG. Laserphotocoagulation of subfoveal neovascular lesions of agerelatedmacular degeneration. Updated findings from two clinical trials.Arch Ophthalmol 1993;111:1200-1209. (58)MPSG. Argon laser photocoagulation for neovascular maculopathy. Fiveyearresults from randomized clinical trials. Arch Ophthalmol 1991;109:1109-1114. (59)MPSG. Laser photocoagulation of subfoveal recurrent neovascular lesionsin age-related maular degeneration. Results of a randomized clinical trial.Arch Ophthalmol 1991;109:1232-1241. (60)MPSG. Laser photocoagulation of subfoveal neovascular lesions in agerelatedmacular degenerations. Results of a randomized clinical trial. ArchOphthalmol 1991;109:1220-1231. (61)MPSG. Risk factors for choroidal neovascularization in the second eye ofpatients with juxtafoveal or subfoveal choroidal neovascularizationsecondary to age-related macular degeneration. Arch Ophthalmol 1997;115:741-747. (62)MPSG. Relationship of drusen and abnormalities of the retinal pigmentepithelium to the prognosis of neovascular macular degeneration. ArchOphthalmol 1990;108:1442-1447. (63)MPSG. Argon laser photocoagulation for senile macular degeneration:results of a randomized clinical trial. Arch Ophthalmol 1982;100:912-918.(64)MPSG. Krypton laser photocoagulation for neovascular lesions of agerelatedmacular degeneration – results of a randomized clinical trial. ArchOphthalmol 1990;108:816-824. (65)MPSG. Persistent and recurrent neovascularization after krypton laser photocoagulationfor neovascular lesions of age-related macular degeneration.Arch Ophthalmol 1990;108:825-831. (66)83
MPSG. Subfoveal neovascular lesions in age-related macular degeneration.Guidelines for evaluation and treatment in the MPS. Arch Ophthalmol1991;109:1242-1257. (67)Murata T, He S, Hangai M et al. Peroxisome proliferator-activated receptor-gammaligands inhibit choroidal neovascularization. IOVS2000;41(8):2309-17. (68)Ninomiya Y, Lewis JM, Hasegawa T, Tana Y. Retinotomy and fovealtranslocation for surgical managements of subfoveal choroidal neova scularmembranes. Am J Ophthalmol 1996;122:613-21. (69)Obana A, Gohto Y, Kanai M et al. Selective photodynamic effects of thenew photosensitizer ATX-S10 (Na) on choroidal neovascularization inmonkeys. Arch Ophthalmol 2000;118:650-658. (70)Ohinmaa et al. Det finske MTV-institut FINOHTA 1999. (71)Olk et al. Therapeutic benefits of infrared (810 nm) diode laser maculargrid photocoagulation in prophylactic treatment of nonexudative agerelatedmacular degeneration: two-year results of a randomized pilot study.Ophthalmol 1999;106:2082-2090. (72)Peyman GA, Moshfeghi DM, Moshfeghi A et al. Photodynamic therapyfor choriocapillaris using Tin Ethyl Etiopurpurin (SnET2). OphthalmicSurg Lasers 1997;28:409-417. (73)Pharmacological Therapy for Macular Degeneration Study Group. InterferonAlfa-2a is ineffective for patients with choroidal neovascularizationsecondary to age-related macular degeneration. Results of a prospectiverandomized placebo-controlled clinical trial. Arch Ophthalmol 1997;115:865-872. (74)Piquet B, Wells JA, Bird AC et al. Age-related Bruch’s membrane change:a clinical study of the relative role of heredity and environment. Br J Ophthalmol1993;77:400-403. (75)The POLA Study. Smoking and age-related macular degeneration. ArchOphthalmol 1998;116:1031-1035. (76)The Radiation theraphy for age-related macular degeneration study group.A prospective, randomized, double-masked trial on radiation theraphy forneovascular age-related macular degeneration (RAD-study). Ophthalmol1999;106:2239-2247. (77)Reichel E, Berrocal AM, Ip M et al. Transpupillary thermotherapy ofoccult subfoveal choroidal neovascularization in patients with age-relatedmacular degeneration. Ophthalmology 1999;106:1908-1914. (78)Rezai KA, Kohen L, Wiedemann P, Heimann K. Iris pigment epitheliumtransplantation. Graefes Arch Clin Exp Ophthalmol 1997;235:558-62.(79)84
Page 2 and 3:
Fotodynamisk behandling afkarnydann
Page 9 and 10:
som rammer erhvervsaktive yngre men
Page 12 and 13:
1IntroduktionAldersrelateret macula
Page 14:
som følge af AMD - vil nå op på
Page 17 and 18:
pension af lipidomsluttede mikrosf
Page 19 and 20:
hos 61% af de behandlede patienter,
Page 22 and 23:
3PatientenGrundsygdommen ARM medfø
Page 24:
nelse, helt op til 87% inden for 5
Page 27 and 28:
TABEL 1Personaletimer pr. behandlin
Page 29 and 30:
man derfor antager, at de fleste pa
Page 31 and 32:
eview af litteratur om incidens af
Page 33 and 34: ehandlede vil have et større overs
Page 35 and 36: ode bevirker diskontering, at forho
Page 37 and 38: sidste rest af centralsyn svinder p
Page 39 and 40: give en behandling med en relativt
Page 42 and 43: 7Ordliste, anvendte forkortelser og
Page 44: QALYretinaserøsstromasubfovealsubr
Page 47 and 48: Communities Study, fandt man en hø
Page 49 and 50: Når AMD medfører symptomer, er de
Page 51 and 52: Bilag 2Eksperimentelle eller uvalid
Page 53 and 54: tion af antioksidanter og zink. Der
Page 55 and 56: TermoterapiI mindre, ukontrollerede
Page 57 and 58: Bilag 3Epidemiologi: Tidligere stud
Page 59 and 60: Bilag 4Incidensopgørelse af potent
Page 61 and 62: henvist til vurdering i hospitalsre
Page 63 and 64: patientbetingede grænser for hvor
Page 65 and 66: Bilag 5Syn, funktionsevne og helbre
Page 67 and 68: den), afstandssynet (Snellen’s bo
Page 69 and 70: ste øje, eller et sammenligneligt
Page 71 and 72: Bilag 6Produktinformation (ved Nova
Page 73 and 74: Udtrængning fra karsystemet (ektra
Page 75 and 76: under ”Særlige advarsler og fors
Page 77 and 78: ProteinbindingI humant fuldblod fin
Page 79 and 80: fortyndes med 5% Glucose til injekt
Page 81 and 82: Blumenkranz MS. Status of photodyna
Page 83: Klein R, Clegg C, Cooper LS et al.
Page 87 and 88: TAP Study Group. Photodynamic Thera
show all

Kun elektronisk udgave - Sundhedsstyrelsen

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?